Drug Type miRNA |
Synonyms MIR-34, MIR-34 MIMIC, MRX 34 + [2] |
Target |
Action inhibitors |
Mechanism miR-34a inhibitors(microRNA 34a inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 2 | - | 01 Aug 2016 | |
Multiple Myeloma | Phase 1 | United States | 01 Apr 2013 | |
Non-Cutaneous Melanoma | Phase 1 | United States | 01 Apr 2013 | |
Non-Small Cell Lung Cancer | Phase 1 | United States | 01 Apr 2013 | |
Primary Malignant Liver Neoplasm | Phase 1 | United States | 01 Apr 2013 | |
Renal Cell Carcinoma | Phase 1 | United States | 01 Apr 2013 | |
Small Cell Lung Cancer | Phase 1 | United States | 01 Apr 2013 |
Phase 1 | 85 | emmqzognpy(dxhacikzem) = 36% all grade nupfybexjg (jrkvepmynt ) View more | - | 26 May 2020 | |||
Phase 1 | 99 | tjrmuurxae(hfregjgera) = MRX34 has a manageable toxicity profile and evidence of activity in HCC, RCC and melanoma hkvikcyauc (auogbuhkrl ) | Positive | 20 May 2016 |